GlassScriptPhysician profile
Devesh Rai
NPI 1639699523
$3,067.41
in general payments reported to CMS, 2019-2025
24 companies · $638 in 2025
The $638 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.93 · 2020: $84.46 · 2021: $518 · 2022: $571 · 2023: $694 · 2024: $548 · 2025: $638.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,765 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,765.20 |
| Education | $115.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $427.92 | 2019-2025 | Jardiance |
| Abbott Laboratories | $406.98 | 2021-2023 | Ensite, Gallant, Mitraclip |
| Boston Scientific Corporation | $247.02 | 2023-2025 | Watchman, Zoom Wireless Transmitter, Watchman Flx |
| Kestra Medical Technology Services, INC. | $245.66 | 2022-2024 | Assure Wcd |
| Janssen Pharmaceuticals, INC | $221.99 | 2020-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $160.19 | 2022-2023 | Camzyos |
| Novartis Pharmaceuticals Corporation | $156.46 | 2024-2025 | |
| Medtronic, INC. | $153.95 | 2022-2024 | Cobalt Dr Mri Surescan |
| Astrazeneca Pharmaceuticals LP | $145.05 | 2022-2025 | Farxiga, Wainua |
| Astellas Pharma US INC | $123.11 | 2021-2022 | |
| W. L. Gore & Associates, INC. | $98.66 | 2022 | |
| Edwards Lifesciences Corporation | $98.46 | 2021-2023 | Sapien 3 Ultra Resilia |
| Amgen INC. | $95.63 | 2022-2025 | Repatha, Repatha |
| Pfizer INC. | $77.37 | 2020-2025 | |
| Novo Nordisk INC | $70.26 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $63.53 | 2025 | Inspire |
| Lantheus Medical Imaging, INC. | $61.25 | 2021-2025 | |
| Scpharmaceuticals INC. | $59.21 | 2024-2025 | |
| Esperion Therapeutics, INC. | $47.00 | 2022 | |
| Merck Sharp & Dohme LLC | $36.98 | 2025 | Verquvo, Capvaxive |
| Melinta Therapeutics, LLC | $21.17 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $18.23 | 2024 | Evkeeza |
| Alnylam Pharmaceuticals INC. | $16.94 | 2024 | Onpattro |
| Abiomed | $14.39 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devesh Rai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.